Incidence and timing of thyroid adverse events in patients with RRMS treated with alemtuzumab through 5 years of the care-MS studies

Authors
Category Primary study
JournalNeurology
Year 2016
This article has no abstract
Epistemonikos ID: fee9143a2d483166a1ead6e68bcaf4ec4df3ca88
First added on: Feb 07, 2025